Gilead Sciences
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 10K+ Employees
View Company Info for Free
Overview
Headquarters
333 Lakeside Dr, Foster City, California...Phone Number
(650) 574-3000Website
www.gilead.comRevenue
$30.5 BillionStock Symbol
GILDIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
3
3
3
2
1
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, InRead more
Gilead Sciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Gilead Sciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Gilead Sciences is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Gilead Sciences has new funding data
Earning: See what the market has to say on Gilead Sciences recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Gilead Sciences
Check if Gilead Sciences has recently received funding, and reach out quickly before it becomes old news!
Click to see if Gilead Sciences had a recent Job posting/layoffs
Product Launch: Get notified when Gilead Sciences launches new products
Gilead Sciences, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Gilead Sciences as Masked Content
Find 3 more new buyers
Compare Similar Companies to Gilead Sciences
Compare insights from companies similar to Gilead Sciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$48.5B
10K+
Public
$4B
1887
Joshua SugrimManager, Chief Technology Officer MSAT Process Validation - CAR T Cell Therapy
Products Owned by Gilead Sciences
Gild
Company Profile Activity
Activity Insights
Gilead Sciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Gilead Sciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Gilead Sciences.
Gilead Sciences financials insights
Gather financial insights about Gilead Sciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
1992
Stock Offering
$86.3M
2024
Other Financing Round
$210M
Gilead Sciences Tech Stack
A closer look at the technologies used by Gilead Sciences
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
Gilead Sciences News & Media
U.S. FDA Approves Gilead's Bixlenvo™, a New Once-Daily Single Tablet Option for ...
– Novel Daily Oral Tablet Combines Bictegravir, a Guideline-Recommended INSTI with a High Barrier to Resistance, with Lenacapavir, a First-in-Class Capsid Inhibitor with No Cross-Resistance to Other Existing Antiretrovirals – – Bixlenvo Now the Smallest STR; First and Only STR for Most People on Complex HIV Treatment Regimens – Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo ™ (bictegravir 75 mg/lenacapavir 50 mg), the smallGilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting
Since earnings, investors have focused mainly on the biotech company's growth potential with its HIV PrEP medicines.3 Dividend Stocks to Hold for the Next 10 Years
These healthcare leaders are unlikely to suspend their dividend programs.European Commission Expands Role of Gilead's Trodelvy® in First-Line Metastatic Triple ...
– European Approval Received for Trodelvy plus Pembrolizumab in First-Line PD-L1-Positive Metastatic Triple-Negative Breast Cancer (TNBC) – – Approval Establishes Trodelvy as the First and Only Antibody-Drug Conjugate for the Treatment of First-Line Metastatic TNBC, Across PD-L1 Status – Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy ® (sacituzumab govitecan-hziy) in combination with Keytruda ® (pembrolizuma
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Gilead Sciences
Sign Up For FreeTo access detailed company insights
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Vek... Read More
